Mantle cell lymphoma (MCL) relapsed or refractory in patients who have previously received at least two lines of systemic therapy including a Bruton tyrosine kinase (BTK) inhibitor; or Chronic ...
Morning Overview on MSN
Study links anti-tumor immunity to autoimmune risks like anti-NMDA encephalitis
Immune checkpoint inhibitors have reshaped cancer treatment over the past decade, but the same immune activation that shrinks tumors can also turn against healthy tissue, including the brain. A ...
In the Phase 3 BRUIN CLL-313 study, treatment with pirtobrutinib demonstrated a highly statistically significant and clinically meaningful improvement in progression-free survival versus bendamustine ...
Erasca (NASDAQ:ERAS) executives outlined the company’s strategy to target RAS-driven cancers and previewed upcoming clinical ...
The dipeptidyl peptidase-1 (DPP1) inhibitor brensocatib became the first licensed therapy for bronchiectasis in the USA and Europe in 2025,1 based on the phase 3 ASPEN trial showing an approximate 20% ...
Colorectal cancer (CRC) arises from genetic and epigenetic alterations, including histone modifications. Unlike genetic changes, epigenetic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results